<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2634">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04615429</url>
  </required_header>
  <id_info>
    <org_study_id>COVID-AT</org_study_id>
    <secondary_id>2020-002193-27</secondary_id>
    <nct_id>NCT04615429</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Assess the Efficacy of MSC in Patients With ARDS Due to COVID-19</brief_title>
  <official_title>Double-blind, Randomized, Controlled, Clinical Trial to Assess the Efficacy of Allogenic Mesenchymal Stromal Cells in Patients With Acute Respiratory Distress Syndrome Due to COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cristina Avendaño Solá</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Puerta de Hierro University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A double-blind, randomized, controlled, clinical trial to evaluate the efficacy and safety of&#xD;
      MSC (mesenchymal stromal cells) intravenous administration in patients with COVID-induced&#xD;
      ARDS compared to a control arm.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A double-blind, randomized, controlled, clinical trial to evaluate the efficacy and safety of&#xD;
      MSC (mesenchymal stromal cells) intravenous administration in patients with COVID-induced&#xD;
      ARDS compared to a control arm.&#xD;
&#xD;
      All trial participants will receive SOC*.&#xD;
&#xD;
      Randomization will be 1:1 between:&#xD;
&#xD;
        -  Treatment arm: allogenic MSC.&#xD;
&#xD;
        -  Control arm: Placebo (solution with the same composition as the experimental treatment,&#xD;
           without the MSC).&#xD;
&#xD;
             -  SOC can include any medicines that are being used in clinical practice (e.g.&#xD;
                lopinavir/ritonavir; hydroxy/chloroquine, tocilizumab, etc.).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 15, 2020</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Actual">January 4, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the PaO2/FiO2* ratio from baseline to day 7 of treatment administration</measure>
    <time_frame>7 days</time_frame>
    <description>Primary endpoint</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>Days 7, 14, and 28 after treatment</time_frame>
    <description>Secondary endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to PaO2/FiO2 ratio greater than 200 mmHg</measure>
    <time_frame>12 months</time_frame>
    <description>Secondary endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical status on the World Health Organization ordinal scale</measure>
    <time_frame>Baseline, daily until day 14, and on day 28 after treatment</time_frame>
    <description>Secondary endpoint.&#xD;
Categories:&#xD;
Not hospitalized, no limitations on activities.&#xD;
Not hospitalized, limitation on activities.&#xD;
Hospitalized, not requiring supplemental oxygen.&#xD;
Hospitalized, requiring supplemental oxygen.&#xD;
Hospitalized, on non-invasive ventilation or high flow oxygen devices.&#xD;
Hospitalized, on invasive mechanical ventilation or ECMO .&#xD;
Death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PaO2/FiO2 ratio</measure>
    <time_frame>Baseline and days 2, 4, 14 and 28 after treatment</time_frame>
    <description>Secondary endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SOFA score</measure>
    <time_frame>Baseline and days 2, 4, 7, 14 and 28 after treatment</time_frame>
    <description>Secondary endpoint Sequential Organ Failure Assessment score (0-24)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen therapy-free days</measure>
    <time_frame>Day 28</time_frame>
    <description>Secondary endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospitalization</measure>
    <time_frame>12 months</time_frame>
    <description>Secondary endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of ICU admission</measure>
    <time_frame>12 months</time_frame>
    <description>Secondary endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of non-invasive ventilation</measure>
    <time_frame>Day 28</time_frame>
    <description>Secondary endpoint Proportion of patients with non-invasive ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of invasive mechanical ventilation</measure>
    <time_frame>Day 28</time_frame>
    <description>Secondary endpoint Proportion of patients with invasive mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of non-invasive ventilation</measure>
    <time_frame>Day 28</time_frame>
    <description>Secondary endpoint (number of days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of invasive mechanical ventilation</measure>
    <time_frame>Day 28</time_frame>
    <description>Secondary endpoint (number of days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mechanical ventilation-free days</measure>
    <time_frame>Day 28</time_frame>
    <description>Secondary endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival rate</measure>
    <time_frame>3 and 12 months.</time_frame>
    <description>Secondary endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence SAEs, Grade 3 and 4 AEs, ADR and AEs of special interest.</measure>
    <time_frame>12 months</time_frame>
    <description>Secondary endpoint</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Analytical endpoints</measure>
    <time_frame>Baseline and days 2, 4, 7, 14 and 28 after treatment</time_frame>
    <description>Exploratory endpoint Analytical markers (e.g., neutrophil and lymphocyte counts). Changes from baseline to set time points will be calculated.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Acute Respiratory Distress Syndrome</condition>
  <condition>COVID-19 Pneumonia</condition>
  <arm_group>
    <arm_group_label>Mesenchymal Stromal cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Approximately 1x10E6 MSC/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Solution identical to experimental treatment, without the MSC</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Mesenchymal stromal cells</intervention_name>
    <description>Administration of one single dose of allogenic Mesenchymal stromal cells</description>
    <arm_group_label>Mesenchymal Stromal cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administration of placebo (solution identical to experimental treatment, without the MSC)</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Informed consent prior to performing study procedures (witnessed oral consent with&#xD;
             written consent by representatives will be accepted to avoid paper handling). Written&#xD;
             consent by patient or representatives will be obtained whenever possible.&#xD;
&#xD;
          2. Adult patients ≥18 years of age at the time of enrolment.&#xD;
&#xD;
          3. Laboratory-confirmed SARS-CoV-2 infection as determined by PCR, in oropharyngeal swabs&#xD;
             or any other relevant specimen obtained during the course of the disease. Alternative&#xD;
             tests (e.g., rapid antigenic tests) are also acceptable as laboratory confirmation if&#xD;
             their specificity has been accepted by the Sponsor.&#xD;
&#xD;
          4. Moderate to severe ARDS (PaO2/FiO2 ratio equal or less than 200 mmHg) for less than 96&#xD;
             hours at the time of randomization.&#xD;
&#xD;
          5. Patients requiring invasive ventilation are eligible within 72 hours from intubation.&#xD;
&#xD;
          6. Eligible for ICU admission, according to the clinical team.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Imminent and unavoidable progression to death within 24 hours, irrespective of the&#xD;
             provision of treatments (in the opinion of the clinical team).&#xD;
&#xD;
          2. &quot;Do Not Attempt Resuscitation&quot; order in place.&#xD;
&#xD;
          3. Any end-stage organ disease or condition, which in the investigator's opinion, makes&#xD;
             the patient an unsuitable candidate for treatment.&#xD;
&#xD;
          4. History of a moderate/severe lung disorder requiring home-based oxygen therapy.&#xD;
&#xD;
          5. Patient requiring ECMO, hemodialysis or hemofiltration at the time of treatment&#xD;
             administration.&#xD;
&#xD;
          6. Current diagnosis of pulmonary embolism.&#xD;
&#xD;
          7. Active neoplasm, except carcinoma in situ or basalioma.&#xD;
&#xD;
          8. Known allergy to the products involved in the allogenic MSC production process.&#xD;
&#xD;
          9. Current pregnancy or lactation (women with childbearing potential should have a&#xD;
             negative pregnancy test result at the time of study enrollment).&#xD;
&#xD;
         10. Current participation in a clinical trial with an experimental treatment for COVID-19&#xD;
             (the use of any off-label medicine according to local treatment protocols is not an&#xD;
             exclusion criteria).&#xD;
&#xD;
         11. Any circumstances that in the investigator's opinion compromises the patient's ability&#xD;
             to participate in the clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rafael F Duarte, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hematology Department. Hospital Universitario Puerta de Hierro</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cristina Avedano-Sola, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Clinical Pharmacology Department. Hospital Universitario Puerta de Hierro</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juan J Rubio, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ICU. Hospital Universitario Puerta de Hierro</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rosa Malo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Respiratory Medicine Department</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro-Majadahonda</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>October 25, 2020</study_first_submitted>
  <study_first_submitted_qc>November 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2020</study_first_posted>
  <last_update_submitted>February 5, 2021</last_update_submitted>
  <last_update_submitted_qc>February 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Puerta de Hierro University Hospital</investigator_affiliation>
    <investigator_full_name>Cristina Avendaño Solá</investigator_full_name>
    <investigator_title>Head of Clinical Pharmacology Deptarment</investigator_title>
  </responsible_party>
  <keyword>Acute Respiratory Distress Syndrome</keyword>
  <keyword>COVID-19 Pneumonia</keyword>
  <keyword>Mesenchymal stromal cells</keyword>
  <keyword>Coronavirus</keyword>
  <keyword>SARS-CoV-2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

